<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Research Results in Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2313-8955-2018-4-3-0-6</article-id><article-id pub-id-type="publisher-id">1516</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>APPROACHES TO CORRECTION OF ISCHEMIC AND REPERFUSION KIDNEY INJURIES IN EXPERIMENT</article-title><trans-title-group xml:lang="en"><trans-title>APPROACHES TO CORRECTION OF ISCHEMIC AND REPERFUSION KIDNEY INJURIES IN EXPERIMENT</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Elagin</surname><given-names>Vladislav V.</given-names></name><name xml:lang="en"><surname>Elagin</surname><given-names>Vladislav V.</given-names></name></name-alternatives><email>vlad.elagin2014@yandex.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Bratchikov</surname><given-names>Oleg I.</given-names></name><name xml:lang="en"><surname>Bratchikov</surname><given-names>Oleg I.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Ulyanova</surname><given-names>Anastasia A.</given-names></name><name xml:lang="en"><surname>Ulyanova</surname><given-names>Anastasia A.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Godovnikova</surname><given-names>Larisa Vladimirovna</given-names></name><name xml:lang="en"><surname>Godovnikova</surname><given-names>Larisa Vladimirovna</given-names></name></name-alternatives><email>godovnikova@bsu.edu.ru</email><xref ref-type="aff" rid="aff1" /></contrib></contrib-group><aff id="aff1"><institution>Belgorod State National Research University</institution></aff><pub-date pub-type="epub"><year>2018</year></pub-date><volume>4</volume><issue>3</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2018/3/ilovepdf_com-64-70.pdf" /><abstract xml:lang="ru"><p>Background:&amp;nbsp;Acute kidney injury is an urgent health problem at the junction of specialties with a high level of disability and mortality of patients. The pertinence of the study stems from conflicting data on the potential mechanisms for preventing this type of injury and the lack of a single therapeutic strategy, despite the possibility of substitution therapy. The aim of the study:&amp;nbsp;To study the possibility of correcting ischemic and reperfusion renal injuries in an experiment with asialo erythropoietin and a selective inhibitor of arginase II KUD975. Materials and methods:&amp;nbsp;In a series of experiments on Wistar male rats, there were studied the renoprotective properties of the prophylactic application of the combination of asialo erythropoietin (2.4 &amp;mu;g/kg 30 minutes before the induction of ischemia) and the selective inhibitor of arginase II KUD975 (120 mg/kg 120 minutes before the induction of ischemia) on a 40-minute bilateral model of renal ischemia-reperfusion. Renoprotective properties were evaluated by the results of biochemical markers of acute renal damage, the dynamics of glomerular filtration rate and fractionated sodium excretion, as well as the severity of microcirculatory disorders. Results:&amp;nbsp;It has been established that the prophylactic use of the combination of asialo erythropoietin KUD975 leads to a decrease in the serum concentration of markers of acute renal damage, an increase in the glomerular filtration rate, a decrease in fractional sodium excretion, and a decrease in microcirculatory disorders. Conclusion:&amp;nbsp;Correction of ischemic and reperfusion renal injuries in the experiment with asialo erythropoietin and selective inhibitor of arginase II KUD975 is an effective strategy for the prevention and treatment of acute kidney injury.</p></abstract><trans-abstract xml:lang="en"><p>Background:&amp;nbsp;Acute kidney injury is an urgent health problem at the junction of specialties with a high level of disability and mortality of patients. The pertinence of the study stems from conflicting data on the potential mechanisms for preventing this type of injury and the lack of a single therapeutic strategy, despite the possibility of substitution therapy. The aim of the study:&amp;nbsp;To study the possibility of correcting ischemic and reperfusion renal injuries in an experiment with asialo erythropoietin and a selective inhibitor of arginase II KUD975. Materials and methods:&amp;nbsp;In a series of experiments on Wistar male rats, there were studied the renoprotective properties of the prophylactic application of the combination of asialo erythropoietin (2.4 &amp;mu;g/kg 30 minutes before the induction of ischemia) and the selective inhibitor of arginase II KUD975 (120 mg/kg 120 minutes before the induction of ischemia) on a 40-minute bilateral model of renal ischemia-reperfusion. Renoprotective properties were evaluated by the results of biochemical markers of acute renal damage, the dynamics of glomerular filtration rate and fractionated sodium excretion, as well as the severity of microcirculatory disorders. Results:&amp;nbsp;It has been established that the prophylactic use of the combination of asialo erythropoietin KUD975 leads to a decrease in the serum concentration of markers of acute renal damage, an increase in the glomerular filtration rate, a decrease in fractional sodium excretion, and a decrease in microcirculatory disorders. Conclusion:&amp;nbsp;Correction of ischemic and reperfusion renal injuries in the experiment with asialo erythropoietin and selective inhibitor of arginase II KUD975 is an effective strategy for the prevention and treatment of acute kidney injury.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>acute kidney injury</kwd><kwd>ischemia-reperfusion</kwd><kwd>asialo erythropoietin</kwd><kwd>inhibitor of arginase II</kwd><kwd>KUD975</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acute kidney injury</kwd><kwd>ischemia-reperfusion</kwd><kwd>asialo erythropoietin</kwd><kwd>inhibitor of arginase II</kwd><kwd>KUD975</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Wang HE, Muntner P,&amp;nbsp;Chertow GM, et al. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol. 2012;35:349-355. https://doi.org/10.1159/000337487</mixed-citation></ref><ref id="B2"><mixed-citation>Kostina DA, Pokrovskaya TG, Olefir YuV, et al. [The role of pharmacological preconditioning in renal ischemic and reperfusion injury]. Urologiya. 2017;5:139-144. Russian.</mixed-citation></ref><ref id="B3"><mixed-citation>Chatauret N, Badet L, Barroua B, et al. Ischemia-reperfusion: from cell biology to acute kidney injury. Prog Urol. 2014;24(1):S4-12. https://doi.org/10.1016/S1166-7087(14)70057-0</mixed-citation></ref><ref id="B4"><mixed-citation>Hussien NI, Emam HT. The potential protective effects of erythropoietin and estrogen on renal ischemia reperfusion injury in ovariectomized rats. Alexandria Journal of Medicine. 2016;52(4):325-335. http://dx.doi.org/10.1016/j.ajme.2015.12.001</mixed-citation></ref><ref id="B5"><mixed-citation>Legrand M, &amp;nbsp;Mik EG, Johannes T, et al. Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med. 2008;14(7-8):502-516. doi:&amp;nbsp;[10.2119/2008-00006.Legrand]</mixed-citation></ref><ref id="B6"><mixed-citation>Banaei S, Ahmadiasl N, Alihemmati A. Сomparison of the protective effects of erythropoietin and melatonin on renal ischemia-reperfusion injury. Trauma Monthly [Internet]. 2016 [cited 2018 August 13]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124127/</mixed-citation></ref><ref id="B7"><mixed-citation>Mofidi A, Bader A, Pavlica S. The use of erythropoietin and its derivatives to treat spinal cord injury. Mini Rev. Med. Chem. 2011;11(9):763-770. doi&amp;nbsp;https://doi.org/10.2174/138955711796355267</mixed-citation></ref><ref id="B8"><mixed-citation>Peresypkina AA. Correction of ischemic optic neuropathy in rats by carbamylated darbepoetin. Research Result: Pharmacology and Clinical Pharmacology. 2018;4(1):43-50. doi: 10.3897/rrpharmacology.4.25262</mixed-citation></ref><ref id="B9"><mixed-citation>Reznikov KM, Gorbunova NS, Kolesnichenko PD, et al. Search of new pharmaceuticals on the basis of darbepoetin in the treatment of ischemic stroke (review of literature). Research result: pharmacology and clinical pharmacology. 2017;3(1):125-136. doi: 10.18413/2500-235X-2017-3-1-125-136.</mixed-citation></ref><ref id="B10"><mixed-citation>Berkowitz DE, White R, Li D, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003;108:2000-2006.</mixed-citation></ref><ref id="B11"><mixed-citation>doi:10.1161/01.CIR.0000092948.04444.C7</mixed-citation></ref><ref id="B12"><mixed-citation>Kudryavtsev KV, Korokin MV, Gudyrev OS. Pharmacological efficacy of an inhibitor of arginase-2 KUD975 with L-NAME-induced endothelial dysfunction. Research result: pharmacology and clinical pharmacology. 2017;3(1):10-17. doi: 10.18413/2500-235X-2017-3-1-10-17</mixed-citation></ref><ref id="B13"><mixed-citation>Yakushev VI, Pokrovskii MV. Cardiovascular effects of an arginase II selective inhibitor. Research result: pharmacology and clinical pharmacology. 2016;2(3):28-46. doi: 10.18413/2500-235X -2016-2-3-28-45</mixed-citation></ref><ref id="B14"><mixed-citation>Raup-Konsavage WM, Gao T, Cooper TK, et al. Arginase-2 mediates renal ischemia-reperfusion injury. American Journal of Physiology &amp;ndash; Renal Physiology. 2017;313(2):F522-F534. doi:10.1152/ajprenal.00620.2016.</mixed-citation></ref></ref-list></back></article>